Released on = May 26, 2006, 6:50 am

Press Release Author = HyperOmics Farma Inc.

Industry = Biotech

Press Release Summary = Following up on the signed agreement between HyperOmics
Farma and the Biotechnology Research Institute (BRI) last year, for the
commercialization of monoclonal antibodies developed through the BRI's Custom
Antibody Service, the first antibody is now available

Press Release Body = Licensing Agreement signed between HyperOmics Farma Inc and the
Biotechnology Research Institute (NRC)

Following up on the signed agreement between HyperOmics Farma and the Biotechnology
Research Institute (BRI) last year, for the commercialization of monoclonal
antibodies developed through the BRI's Custom Antibody Service, the first antibody
(anti-GST) is now available. As per the commercialization agreement, HyperOmics has
the sole rights to all antibodies from this Service platform for research and all
"non-therapeutic" purposes. As per the agreement signed, this first antibody is now
commercially available through HyperOmics Farma.

\"We are honoured to be working alongside pre-eminent scientists such as Dr. Malcolm
Whiteway," said HyperOmics Farma President Michel Dominguez. "We are pleased to be
able to commercialize the high quality antibodies generated by this team and we hope
that this is the beginning of a long and mutually satisfying relationship."
The first antibody against Glutathione S-Transferase (GST) is an essential tool for
research. GST fusion proteins are one of the major systems used for protein
expression and purification. This newly developed antibody is exceptional in that
it can be used at the low nanogram per ml range as compared to a working dilution
that is one order of magnitude higher for other commercially available anti-GST
antibodies. Moreover, this new antibody recognizes both native and denatured forms
of the protein.

HyperOmics and the BRI are also working on new monoclonal antibodies that they plan
to have available by the beginning of 2006.

About HyperOmics Farma
HyperOmics Farma, dedicated to offering the best products to scientists, is a
private biotechnology company based in Montreal Canada. We are involved in the
production of custom-made primary antibodies and the supply of complementary
reagents. As an ideal solution for proteomics-based protein discovery platforms, we
will provide you with a means to gain insight into the function of known and novel
proteins, receptors, signalling molecules, and regulatory proteins enabling you to
validate proteins as effective drug targets or valuable serum biomarkers necessary
for the diagnosis and treatment of disease.
For more information about HyperOmics Farma, go to www. hyperomics.com

About NRC-BRI

The NRC Biotechnology Research Institute (www.bri.nrc.gc.ca) is the largest NRC
laboratory in Canada dedicated to R&D in biotechnology. More than 800 people,
including NRC personnel, students, guest researchers and scientists, work in three
main sectors of research: health, bioprocess and environment and in the Industrial
Partnership Facility. It maintains ties with industry and universities to generate
benefits for Canada. The Environment Sector of the NRC-BRI undertake research
programs in two strategic areas: environmental protection and eco-efficient
industrial production (clean manufacturing).

For more information contact:
Dr. Elizabeth.cooper, MBA
HyperOmics Farma Inc.
Tel: +1(514)349-9119
e-mail: Elizabeth.cooper@hyperomics.com


Web Site = http://www.hyperomics.com

Contact Details = Dr. Elizabeth.cooper, MBA
HyperOmics Farma Inc.
P.B. 12 Succ.
Pierrefonds, QC
H9H 4K8
Canada
Tel: +1(514)349-9119
e-mail: Elizabeth.cooper@hyperomics.com